Quick Takeaways
- ANNX - Annexon, Inc. has 17 insiders with reported activity on this page.
- Net insider value flow over the last year: +$8,660,968.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 17 Insiders of Annexon, Inc.
- Symbol
- ANNX on Nasdaq
- Location
- Brisbane, CA
What Changed
- Buy value: $8,982,383; sell value: $321,415.
- Net share flow: +2,337,635.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to buying over the last 12 months. Net value: +$8,660,968.
Buys
$8,982,383
Shares: 2,400,418
Insiders: 3
Sells
$321,415
Shares: 62,783
Insiders: 5
Net
+$8,660,968
Shares: +2,337,635
Insiders: -2
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 16,000 | 59,697 | $94,960 | $313,428 | -$218,468 |
| 3-6 | 2,367,958 | 0 | $8,846,150 | $0 | +$8,846,150 |
| 6-9 | 12,345 | 0 | $31,151 | $0 | +$31,151 |
| 9-12 | 4,115 | 3,086 | $10,123 | $7,987 | +$2,135 |
Annexon, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Muneer A. Satter | Director | $41,638,566 | +$8,655,784 | +26% | Filing P/S | 20 Nov 2025 |
| Bain Capital Life Sciences Investors, LLC | 10%+ Owner | $24,428,590 | Mixed | 25 May 2023 | ||
| Michael Overdorf | Evp & Chief Business Officer | $989,827 | -$57,491 | -5.5% | Filing P/S | 02 Mar 2026 |
| Dean Richard Artis | Evp & Chief Scientific Officer | $977,904 | -$58,983 | -5.7% | Filing P/S | 02 Mar 2026 |
| Jennifer Lew | Evp & Chief Financial Officer | $925,194 | -$73,163 | -7.3% | Filing P/S | 02 Mar 2026 |
| Ted Yednock | Evp & Chief Innovation Officer | $835,552 | -$73,196 | -8.1% | Filing P/S | 02 Mar 2026 |
| Jamie Dananberg | Chief Medical Officer | $671,050 | -$58,582 | -8% | Filing P/S | 02 Mar 2026 |
| William H. Carson | Director | $436,511 | +$188,329 | +76% | Filing P/S | 10 Apr 2026 |
| Jung Choi | Director | $138,270 | +$138,270 | +100% | Filing P/S | 01 Dec 2025 |
| Larry Mattheakis | EVP & Chief Scientific Officer | $77,728 | Mixed | 11 Jul 2022 | ||
| Sanjay Chandru Keswani | EVP & Chief Medical Officer | $56,528 | Mixed | 11 Feb 2022 | ||
| Bettina M. Cockroft | Director | Mixed | 05 Jun 2025 | |||
| Douglas Love | PRESIDENT AND CEO, Director | Mixed | 19 Feb 2026 | |||
| William A. Jones Jr. | Director | Mixed | 05 Jun 2025 | |||
| William D. Waddill | Director | Mixed | 05 Jun 2025 | |||
| Ricky Sun | Director | Mixed | 02 Jun 2021 | |||
| Thomas G. Wiggans | Director | Mixed | 05 Jun 2025 |
Top shareholders of Annexon, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC |
13D/G
13F
|
Company |
9.9%
|
15,427,866
|
$85,778,935 | $0 | 31 Dec 2025 | |
| FMR LLC |
13D/G
13F
|
Company |
7.1%
|
10,222,470
|
$51,316,801 | -$4,310,639 | 31 Dec 2025 | |
| BVF INC/IL |
13F
|
Company |
5.9%
|
9,128,080
|
$45,822,962 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.1%
from 13D/G
|
8,960,434
|
$44,981,380 | — | 31 Dec 2025 | |
| Muneer A. Satter |
3/4/5
13D/G
|
Director · Satter Muneer A |
7.2%
from 13D/G
|
9,783,637
mixed-class rows
|
$41,638,566 | +$8,655,784 | 20 Nov 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5%
|
7,753,387
|
$38,922,003 | — | 31 Dec 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
3.5%
|
5,500,000
|
$27,610,000 | — | 31 Dec 2025 | |
| Bain Capital Life Sciences Investors, LLC |
13F
3/4/5
|
Company · 10%+ Owner |
3.4%
|
5,249,069
|
$26,350,326 | — | 31 Dec 2025 | |
| Bellevue Group AG |
13F
|
Company |
3.3%
|
5,157,290
|
$25,889,596 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
3%
|
4,652,185
|
$23,353,969 | — | 31 Dec 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
2.8%
|
4,348,782
|
$21,830,887 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
2.6%
|
4,000,074
|
$20,080,371 | — | 31 Dec 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
2.1%
|
3,299,256
|
$16,562,265 | — | 31 Dec 2025 | |
| Longaeva Partners L.P. |
13F
|
Company |
2%
|
3,100,000
|
$15,562,000 | — | 31 Dec 2025 | |
| MAK CAPITAL ONE LLC |
13F
|
Company |
1.9%
|
2,958,527
|
$14,851,806 | — | 31 Dec 2025 | |
| Nuveen, LLC |
13F
|
Company |
1.9%
|
2,915,324
|
$14,634,927 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
2,902,896
|
$14,576,148 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.8%
|
2,856,143
|
$14,337,838 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.8%
|
2,836,857
|
$14,241,022 | — | 31 Dec 2025 | |
| Opaleye Management Inc. |
13F
|
Company |
1.7%
|
2,600,000
|
$13,052,000 | — | 31 Dec 2025 | |
| Palo Alto Investors LP |
13F
|
Company |
1.5%
|
2,384,192
|
$11,968,644 | — | 31 Dec 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
1.5%
|
2,381,479
|
$11,955,025 | — | 31 Dec 2025 | |
| Tetragon Partners GP Ltd |
13F
|
Company |
1.3%
|
2,032,455
|
$10,202,924 | — | 31 Dec 2025 | |
| Bain Capital Life Sciences Fund, L.P. |
13D/G
|
BCLS I Investco, LP |
4.9%
|
5,249,069
|
$9,973,231 | $0 | 31 Dec 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.1%
|
1,768,745
|
$8,879,100 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1%
|
1,605,581
|
$8,060,016 | — | 31 Dec 2025 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.84%
|
1,316,212
|
$6,607,384 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.68%
|
1,057,060
|
$5,306,441 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.67%
|
1,046,221
|
$5,252,029 | — | 31 Dec 2025 | |
| J. Goldman & Co LP |
13F
|
Company |
0.64%
|
993,795
|
$4,988,851 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.62%
|
972,449
|
$4,881,694 | — | 31 Dec 2025 | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ |
13F
|
Company |
0.58%
|
903,439
|
$4,535,264 | — | 31 Dec 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.55%
|
861,245
|
$4,321,000 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.52%
|
802,600
|
$4,029,052 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.51%
|
792,000
|
$3,975,840 | — | 31 Dec 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.5%
|
776,307
|
$3,897,061 | — | 31 Dec 2025 | |
| Ishara Investments LP |
13F
|
Company |
0.48%
|
750,000
|
$3,765,000 | — | 31 Dec 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.46%
|
718,680
|
$3,607,910 | — | 31 Dec 2025 | |
| SIRIOS CAPITAL MANAGEMENT L P |
13F
|
Company |
0.46%
|
710,256
|
$3,565,485 | — | 31 Dec 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.44%
|
683,879
|
$3,433,073 | — | 31 Dec 2025 | |
| Russell Investments Group, Ltd. |
13F
|
Company |
0.44%
|
683,016
|
$3,428,739 | — | 31 Dec 2025 | |
| MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.41%
|
642,038
|
$3,223,031 | — | 31 Dec 2025 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.41%
|
639,902
|
$3,212,308 | — | 31 Dec 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.39%
|
601,202
|
$3,018,034 | — | 31 Dec 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
0.37%
|
583,913
|
$2,931,243 | — | 31 Dec 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.37%
|
573,748
|
$2,880,214 | — | 31 Dec 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.36%
|
560,744
|
$2,814,935 | — | 31 Dec 2025 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.34%
|
534,986
|
$2,685,630 | — | 31 Dec 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.34%
|
522,846
|
$2,624,686 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.33%
|
520,998
|
$2,615,410 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Annexon, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| William H. Carson | ANNX | Common Stock | Purchase | 12.8% | $49,600 | $6.20 | 8,000 | 70,405 | 10 Apr 2026 | Direct |
| William H. Carson | ANNX | Common Stock | Purchase | 14.7% | $45,360 | $5.67 | 8,000 | 62,405 | 10 Mar 2026 | Direct |
| Jamie Dananberg | ANNX | Common Stock | Sale | -4.5% | $31,603 | $5.43 | -5,820 | 123,582 | 02 Mar 2026 | Direct |
| Michael Overdorf | ANNX | Common Stock | Sale | -2.32% | $23,517 | $5.42 | -4,339 | 182,625 | 02 Mar 2026 | Direct |
| Ted Yednock | ANNX | Common Stock | Sale | -3.48% | $30,168 | $5.42 | -5,566 | 154,161 | 02 Mar 2026 | Direct |
| Dean Richard Artis | ANNX | Common Stock | Sale | -3.17% | $32,004 | $5.43 | -5,894 | 180,093 | 02 Mar 2026 | Direct |
| Jennifer Lew | ANNX | Common Stock | Sale | -3.16% | $30,162 | $5.42 | -5,565 | 170,700 | 02 Mar 2026 | Direct |
| Douglas Love | ANNX | Stock Option (Right to Buy) | Award | 1,250,000 | 1,250,000 | 19 Feb 2026 | Direct | |||
| Jamie Dananberg | ANNX | Common Stock | Award | 76.9% | 56,250 | 129,402 | 19 Feb 2026 | Direct | ||
| Jamie Dananberg | ANNX | Stock Option (Right to Buy) | Award | 225,000 | 225,000 | 19 Feb 2026 | Direct | |||
| Michael Overdorf | ANNX | Common Stock | Award | 50.2% | 62,500 | 186,964 | 19 Feb 2026 | Direct | ||
| Michael Overdorf | ANNX | Stock Option (Right to Buy) | Award | 250,000 | 250,000 | 19 Feb 2026 | Direct | |||
| Dean Richard Artis | ANNX | Common Stock | Award | 50.6% | 62,500 | 185,987 | 19 Feb 2026 | Direct | ||
| Dean Richard Artis | ANNX | Stock Option (Right to Buy) | Award | 250,000 | 250,000 | 19 Feb 2026 | Direct | |||
| Ted Yednock | ANNX | Common Stock | Award | 64.3% | 62,500 | 159,727 | 19 Feb 2026 | Direct | ||
| Ted Yednock | ANNX | Stock Option (Right to Buy) | Award | 250,000 | 250,000 | 19 Feb 2026 | Direct | |||
| Jennifer Lew | ANNX | Common Stock | Award | 54.9% | 62,500 | 176,265 | 19 Feb 2026 | Direct | ||
| Jennifer Lew | ANNX | Stock Option (Right to Buy) | Award | 250,000 | 250,000 | 19 Feb 2026 | Direct | |||
| Jamie Dananberg | ANNX | Common Stock | Sale | -6.74% | $26,979 | $5.10 | -5,290 | 73,152 | 18 Feb 2026 | Direct |
| Jennifer Lew | ANNX | Common Stock | Sale | -6.46% | $40,119 | $5.11 | -7,851 | 113,765 | 18 Feb 2026 | Direct |
| Dean Richard Artis | ANNX | Common Stock | Sale | -4.11% | $26,979 | $5.10 | -5,290 | 123,487 | 18 Feb 2026 | Direct |
| Ted Yednock | ANNX | Common Stock | Sale | -7.48% | $40,149 | $5.11 | -7,857 | 97,227 | 18 Feb 2026 | Direct |
| Michael Overdorf | ANNX | Common Stock | Sale | -4.76% | $31,748 | $5.10 | -6,225 | 124,464 | 18 Feb 2026 | Direct |
| William H. Carson | ANNX | Common Stock | Purchase | 8.18% | $20,657 | $5.02 | 4,115 | 54,405 | 30 Dec 2025 | Direct |
| Jung Choi | ANNX | Common Stock | Purchase | $138,270 | $4.19 | 33,000 | 33,000 | 01 Dec 2025 | By Trust | |
| William H. Carson | ANNX | Common Stock | Purchase | 8.91% | $18,394 | $4.47 | 4,115 | 50,290 | 01 Dec 2025 | Direct |
| Muneer A. Satter | ANNX | Common Stock | Purchase | 4.54% | $1,808,784 | $4.28 | 422,613 | 9,728,637 | 21 Nov 2025 | See footnote |
| Muneer A. Satter | ANNX | Common Stock | Purchase | 4.49% | $1,792,000 | $4.48 | 400,000 | 9,306,024 | 20 Nov 2025 | See footnote |
| Muneer A. Satter | ANNX | Common Stock | Purchase | 5.95% | $1,970,000 | $3.94 | 500,000 | 8,906,024 | 19 Nov 2025 | See footnote |
| Muneer A. Satter | ANNX | Common Stock | Purchase | 6.32% | $1,590,000 | $3.18 | 500,000 | 8,406,024 | 18 Nov 2025 | See footnote |
| Muneer A. Satter | ANNX | Common Stock | Purchase | 6.75% | $1,495,000 | $2.99 | 500,000 | 7,906,024 | 17 Nov 2025 | See footnote |
| William H. Carson | ANNX | Common Stock | Purchase | 9.78% | $13,045 | $3.17 | 4,115 | 46,175 | 30 Oct 2025 | Direct |
| William H. Carson | ANNX | Common Stock | Purchase | 10.8% | $12,551 | $3.05 | 4,115 | 42,060 | 30 Sep 2025 | Direct |
| William H. Carson | ANNX | Common Stock | Purchase | 12.2% | $8,600 | $2.09 | 4,115 | 37,945 | 02 Sep 2025 | Direct |
| William H. Carson | ANNX | Common Stock | Purchase | 13.8% | $9,999 | $2.43 | 4,115 | 33,830 | 30 Jul 2025 | Direct |
| Ted Yednock | ANNX | Common Stock | Sale | -1.05% | $2,879 | $2.58 | -1,116 | 105,084 | 14 Jul 2025 | Direct |
| Jennifer Lew | ANNX | Common Stock | Sale | -0.91% | $2,882 | $2.58 | -1,117 | 121,616 | 14 Jul 2025 | Direct |
| Michael Overdorf | ANNX | Common Stock | Sale | -0.65% | $2,226 | $2.61 | -853 | 130,689 | 14 Jul 2025 | Direct |
| William H. Carson | ANNX | Common Stock | Purchase | 16.1% | $10,123 | $2.46 | 4,115 | 29,715 | 30 Jun 2025 | Direct |
| Thomas G. Wiggans | ANNX | Stock Option (Right to Buy) | Award | 55,000 | 55,000 | 05 Jun 2025 | Direct | |||
| Muneer A. Satter | ANNX | Stock Option (Right to Buy) | Award | 55,000 | 55,000 | 05 Jun 2025 | Direct | |||
| William D. Waddill | ANNX | Stock Option (Right to Buy) | Award | 55,000 | 55,000 | 05 Jun 2025 | Direct | |||
| William H. Carson | ANNX | Stock Option (Right to Buy) | Award | 55,000 | 55,000 | 05 Jun 2025 | Direct | |||
| Jung Choi | ANNX | Stock Option (Right to Buy) | Award | 55,000 | 55,000 | 05 Jun 2025 | Direct | |||
| William A. Jones Jr. | ANNX | Stock Option (Right to Buy) | Award | 55,000 | 55,000 | 05 Jun 2025 | Direct | |||
| Bettina M. Cockroft | ANNX | Stock Option (Right to Buy) | Award | 55,000 | 55,000 | 05 Jun 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.